FULC · Fulcrum Therapeutics, Inc. · Metrics
$3.69
-0.02 (-0.41%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$285.35M
Shares
76.30M
Volume · Oct 1
1.02M
Avg daily vol (3M)
1.6M
FULC metrics
54 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$3.70
Market cap
$285.35M
Price action
20 metricsPrice change (1W)
-2.9%
Price change (30D)
-4.4%
Price change (3M)
+1.6%
Price change (6M)
-50.5%
Price change (YTD)
-67.3%
Price change (1Y)
-59.8%
Trailing year
Price change (5Y)
-86.9%
52-week high
$14.60
52-week low
$3.14
Change from 52-week high
-74.7%
Change from 52-week low
+17.8%
Annualized volatility
95.4%
Annualized volatility (3M)
27.8%
Beta
0.8
RSI (14D)
37.8
Price vs SMA 50
-2.2%
Price vs SMA 200
-44.8%
Avg volume (3M)
1.60M
Relative volume
1.2
Average dollar volume
$6.02M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
76.30M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.9
reciprocal yield 108.9%
FCF yield
-23.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-29.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-04-27
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$96.05M
Net income (TTM)
−$85.00M
Trailing 12 months
Diluted EPS (TTM)
$-1.21
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-27.4%
Return on assets
-26.2%
Debt / equity
—
Current ratio
31.4
EBITDA (TTM)
—
Free cash flow (TTM)
−$66.14M
Quick ratio
31.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$48.47M
Total assets
$323.95M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$65.78M
Capital expenditures (TTM)
$365,000
R&D (TTM)
$56.24M
SG&A (TTM)
—
Stock compensation (TTM)
$13.56M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
154
13F filer change QoQ
-15
Institutional ownership
104.9%
Short interest
3 metricsShort interest
9.4%
Latest settlement · 5.9 days to cover
Days to cover
5.9d
Short-squeeze score
76 / 100
Insider activity
2 metricsNet insider buying (90D)
$1.49M
Insider-sentiment score
88 / 100
Risk flags
1 metricsGoing concern
—